Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial.

ABSTRACT:

Background

Sex differences in the incidence and outcomes of several cancers are well established. Multiple myeloma (MM) is a malignant plasma cell dyscrasia accounting for 2% of all new cancer cases in the UK. There is a clear sex disparity in MM incidence, with 57% of cases in males and 43% in females. The mechanisms behind this are not well understood and the impact of sex on patient outcomes has not been thoroughly explored.

Patients and methods

We investigated the association of sex with baseline disease characteristics and outcome in 3894 patients recruited to the phase III UK NCRI Myeloma XI trial, in which treatment exposure to lenalidomide predominated.

Results

Females were significantly more likely to have the molecular lesions t(14;16) and del(17p) and were

SUBMITTER: Bird S 

PROVIDER: S-EPMC8528179 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature